Lower optimal dose of amrubicin for relapsed small-cell lung cancer: a retrospective study.

Shinji NakamichiKaoru KubotaFenfei ZouAnna HayashiNatsuki TakanoNaomi OndaMasaru MatsumotoAkihiko MiyanagaRintaro NoroMasahiro Seike

Published in: International journal of clinical oncology (2023)

, without any significant difference in efficacy. Lower dose of AMR for relapsed SCLC could be a promising treatment option.

Keyphrases